• 2018 Course Dates and Locations Coming Soon!

    Agenda At-a-Glance*

    * Please note the track order below does not reflect the individual agendas for each live course. Please see the live course locations tab for a detailed agenda.

    Women's Cancers Track

    Ovarian Cancer:
    New Insights into Biology and Treatment
    Ursula A. Matulonis, MD

    HER2 Positive and Triple-Negative Breast Cancers: Making Individualized Treatment Selections in First and Later Line Settings
    Eric P. Winer, MD

    ER Positive Breast Cancers:
    Impact of Recent Clinical Trial Results on Therapeutic Decision-Making
    Harold J. Burstein, MD, PhD

    Panel Discussion
    All Supportive Care and Women's Cancers Track Faculty

    Supportive Care Track

    Supportive and Palliative Care:
    Managing Symptoms and Improving Patient Outcomes
    Janet L. Abrahm, MD

    Identifying and Meeting the Medical and Psychological Needs of Cancer Survivors
    Ann H. Partridge, MD, MPH

    Genitourinary Cancers Track

    Prostate Cancer:
    Evidence-Based Treatment Selection for Advanced and Metastatic Disease
    Philip W. Kantoff, MD / Mark M. Pomerantz, MD

    Bladder and Renal Cancers:
    Current Guideline-Based Management and Emerging Treatment Targets
    Robert Dreicer, MD

    Head, Neck and Lung Cancers Track

    Head and Neck and Thyroid Cancers:
    Incorporating New Therapies into Current Treatment Algorithms
    Robert I. Haddad, MD

    Non-Small Cell and Small Cell Lung Cancer:
    Patient Selection for Immune-Based, Targeted, and Chemotherapeutic Treatment Options
    Bruce E. Johnson, MD

    Melanoma Cancer Track

    New Therapies for Advanced and Metastatic Disease and Recent Developments in Adjuvant Treatment
    F. Steven Hodi Jr., MD / Antoni Ribas, MD / Jedd D. Wolchok, MD, PhD

    Panel Discussion
    All Head, Neck and Lung Cancers and Melanoma Cancer Track Faculty

    Sarcoma Track

    GIST and Soft Tissue Sarcomas:
    Applying Recent Clinical Advances in Systemic Therapy in the Adjuvant and Metastatic Settings
    George D. Demetri, MD

    Gastrointestinal Cancer Track

    Esophagogastic and Pancreatic Cancers:
    Evidence-Based Use of Systemic Therapies in the Adjuvant and Metastatic Settings
    Peter C. Enzinger, MD

    Hereditary Gastrointestinal Cancers::
    Advances in Genetics and Current Management
    Sapna Syngal, MD, MPH / Matthew B. Yurgelun, MD

    Role of Diet and Lifestyle in the Primary and Secondary Prevention of Gastrointestinal Cancers
    Charles S. Fuchs, MD, MPH / Kimmie Ng, MD, MPH

    Colorectal Cancer:
    Selecting Systemic Therapies in the Adjuvant and Metastatic Settings based on Patient and Disease Characteristics
    Robert J. Mayer, MD

    Panel Discussion
    All Gastrointestinal Cancers Track Faculty

    Hematologic Malignancies Track

    Non-Hodgkin and Hodgkin Lymphoma:
    Using Patient and Disease Characteristics as a Guide to Treatment Selection
    Arnold S. Freedman, MD

    Myeloid Malignancies:
    Current and Emerging Treatment Approaches in First and Later Line Settings
    Daniel J. DeAngelo, MD, PhD / Richard M. Stone, MD

    Myeloproliferative Neoplasms:
    Individualized Treatment Based on Risk Stratification
    Ayalew Tefferi, MD

    Multiple Myeloma:
    Optimal Selection and Sequencing of Systemic Therapies
    Kenneth C. Anderson, MD

    Chronic Lymphocytic Leukemia:
    Incorporating Expanded Treatment Options into Current Management Paradigms
    John C. Byrd, MD

    Management of Thrombosis and Hypercoaguable Conditions in the Cancer Patient
    Jean M. Connors, MD

    Panel Discussion
    All Hematologic Malignancies Track Faculty

    Course Goal and Overview

    The goal of this course is to assist oncologists with assessing and improving their skills in the diagnosis, treatment, and overall management of a wide range of common cancers.

    This innovative, live two-day curriculum provides a comprehensive update of oncologic practice, including current best practices and updated guidelines, emerging clinical evidence, and recent expert opinion in nearly all major areas of practice. Highly interactive presentations are followed by lively discussion sessions, including both Q&A and panel discussion formats. Learners are encouraged to bring their most difficult cases and clinical questions, building clinical skills through exposure to practice and patient care standards set by the acknowledged master clinicians of DFCI.

    Target Audience

    This course is intended for Medical Oncologists seeking an in depth review of the latest treatment advances in oncology.

    Maintenance of Certification (MOC) Session***

    *** Please sign up when registering for the course to participate in our optional MOC session.

    Optional Maintenance of Certification (MOC Part II ) Session 2017 Updates in Oncology

    Harold J. Burstein, MD, PhD
    Daniel J. DeAngelo, MD, PhD
    Robert J. Mayer, MD
    Richard M. Stone, MD

  • Acknowledgments

    Dana-Farber Cancer Institute gratefully acknowledges the following organizations for providing educational grants or financial support at the time of print for this activity.

    Ambry Genetics Ariad AstraZeneca
    Bayer HealthCare Boehringer Ingelheim Bristol-Myers Squibb
    Celgene Elsai Ferring
    Genomic Health Lilly Janssen Biotech
    Millennium Novartis Pfizer
    Sanofi Taiho Oncology Tesaro